Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Norvasc Challenges: Mylan ANDA, Dr. Reddy’s 505(b)(2)

Executive Summary

Pfizer's Norvasc patent suit against Mylan could still delay the launch of Mylan's generic amlodipine, despite the lack of a 30-month stay
Advertisement

Related Content

Pfizer Norvasc Patent: Will Court Limit Extension To “Approved” Product?
Pfizer Norvasc Patent: Will Court Limit Extension To “Approved” Product?
PhRMA Wants Amended ANDAs To Trigger 30-Month Stays
PhRMA Wants Amended ANDAs To Trigger 30-Month Stays
Pfizer Norvasc Patent Term Extension Coverage: The Product Or The Use?
Pfizer Norvasc Patent Term Extension Coverage: The Product Or The Use?
Pfizer, Pharmacia Protest Inclusion Of Drug Innovator Data In "Paper NDAs"
Generics With Poor Bioavailability May Not Use 505(b)(2) "Paper" NDA
Bristol mail room mishap permitted Geneva generic captopril approval -- BMS testimony.
Bristol mail room mishap permitted Geneva generic captopril approval -- BMS testimony.
Advertisement
UsernamePublicRestriction

Register

PS040661

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel